The IV formulation of edaravone was approved under the brand name Radicava ® in May 2017 for the treatment of ALS. The retrospective, observational, comparative effectiveness cohort study utilized ...

The study suggests that, in patients with amyotrophic lateral sclerosis (ALS), treatment with intravenous (IV) RADICAVA ® (edaravone) was associated with fewer reported disease progression ...

The approval by the US Food and Drug Administration (USFDA) is for Edaravone injection of strengths ... to the reference listed drug (RLD), Radicava injection, 30 mg/100 ml and 60 mg/100 ml ...

Mitsubishi Tanabe Pharma has withdrawn its EU application for ALS drug Radicava (edaravone), citing ‘unwarranted’ additional data requirements from the EMA. The drug has been approved in the ...

Please provide your email address to receive an email when new articles are posted on . The treatment group logged longer times to four disease-progression milestones compared with controls.

In 2024, it launched Edaravone injection, used to treat amyotrophic lateral sclerosis (ALS), and a new concentration of Zinc Sulfate for injection, which followed the Pantoprazole Sodium ...

The IV formulation of edaravone was approved under the brand name Radicava ® in May 2017 for the treatment of ALS. The retrospective, observational, comparative effectiveness cohort study ...